BEIJING & CAMBRIDGE, Mass.–EdiGene Inc., which develops genome editing technologies into novel therapeutics for a broad range of diseases and into creative solutions to advance drug discovery, today announced the successful completion of approximately $15 Million in a Series pre-B financing. The financing is led by new investor Lilly Asia Ventures (LAV). New investor Huagai

To read the full story...

Already a subscriber? Login now

< | >